NVS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...

Stats
Объем за сегодня	1.46M
Средний объем	1.63M
Рыночная капитализация	190.64B
EPS	$0 ( 2024-04-23 )
Дата следующего отчета о доходах	( $1.850 ) 2024-07-16
Last Dividend	$3.47 ( 2023-03-09 )
Next Dividend	$0 ( N/A )
P/E	22.15
ATR14	$0.0230 (0.02%)

Объем Корреляция

Длинно: -0.67 (moderate negative)

Кратко: -0.82 (strong negative)

Signal:(23.382) Be Aware. Possible trading coming up! (swing)

Novartis AG Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Novartis AG Корреляция - Валюта/Сырье

-0.04
( neutral )

0.12
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.19
( neutral )

-0.51
( weak negative )

Novartis AG Финансовые показатели

Annual	2023
Выручка:	$46.66B
Валовая прибыль:	$34.19B (73.27 %)
EPS:	$7.15

FY	2023
Выручка:	$46.66B
Валовая прибыль:	$34.19B (73.27 %)
EPS:	$7.15

FY	2022
Выручка:	$51.83B
Валовая прибыль:	$36.34B (70.12 %)
EPS:	$3.19

FY	2021
Выручка:	$52.88B
Валовая прибыль:	$37.01B (69.99 %)
EPS:	$10.71

Financial Reports:

No articles found.

Novartis AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$3.47 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novartis AG Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.42 - Stable (8.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.966	2000-11-14
Last Dividend	$3.47	2023-03-09
Next Dividend	$0	N/A
Payout Date	2023-03-20
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$44.60	--
Avg. Dividend % Per Year	2.46%	--
Score	4.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.42
Div. Directional Score	7.88	--

Next Divdend (Est)
(2025-01-10)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

4.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	$0.966	2.96%
2001	$0.450	1.12%
2002	$0.468	1.46%
2003	$0.627	1.89%
2004	$0.722	1.57%
2005	$0	0.00%
2006	$0.801	1.50%
2007	$0.969	1.67%
2008	$1.319	2.42%
2009	$1.541	3.11%
2010	$1.780	3.38%
2011	$2.11	3.56%
2012	$2.20	3.78%
2013	$2.27	3.56%
2014	$2.44	3.10%
2015	$2.52	2.73%
2016	$2.47	2.88%
2017	$2.46	3.38%
2018	$2.67	3.15%
2019	$2.57	3.06%
2020	$3.04	3.20%
2021	$3.38	3.58%
2022	$3.36	3.82%
2023	$3.47	3.76%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.307	1.500	3.86	5.79	[0 - 0.5]
returnOnAssetsTTM	0.162	1.200	4.61	5.54	[0 - 0.3]
returnOnEquityTTM	0.346	1.500	7.27	10.00	[0.1 - 1]
payoutRatioTTM	0.342	-1.000	6.58	-6.58	[0 - 1]
currentRatioTTM	0.903	0.800	-0.485	-0.388	[1 - 3]
quickRatioTTM	0.613	0.800	-1.102	-0.881	[0.8 - 2.5]
cashRatioTTM	0.323	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.273	-1.500	5.45	-8.17	[0 - 0.6]
interestCoverageTTM	12.32	1.000	6.55	6.55	[3 - 30]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.96	2.00	7.52	10.00	[0 - 20]
debtEquityRatioTTM	0.649	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.726	1.000	1.237	1.237	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.534	1.000	8.14	8.14	[0.2 - 2]
assetTurnoverTTM	0.526	0.800	9.83	7.86	[0.5 - 2]
Total Score				10.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.346	2.50	8.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.96	2.00	8.35	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
payoutRatioTTM	0.342	1.500	6.58	-6.58	[0 - 1]
pegRatioTTM	-3.02	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.277	1.000	5.57	0	[0.1 - 0.5]
Total Score				5.42

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.